Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
Trial ID or NCT#
Transient ischemic attack (TIA) is a transient neurological deficit (speech disturbance, weakness…), caused by temporary occlusion of a brain vessel by a blood clot that leaves no lasting effect. TIA diagnosis can be challenging and an expert stroke evaluation combined with magnetic resonance imaging (MRI) could improve the diagnosis accuracy. The risk of a debilitating stroke can be as high as 5% during the first 72 hrs after TIA. TIA characteristics (duration, type of symptoms, age of the patient), the presence of a significant narrowing of the neck vessels responsible for the patient's symptoms (symptomatic stenosis), and an abnormal MRI are associated with an increased risk of stroke. An emergent evaluation and treatment of TIA patients by a stroke specialist could reduce the risk of stroke to 2%. Stanford has implemented an expedited triage pathway for TIA patients combining a clinical evaluation by a stroke neurologist, an acute MRI of the brain and the vessels and a sampling of biomarkers (Lp-PLA2). The investigators are investigating the yield of this unique approach to improve TIA diagnosis, prognosis and secondary stroke prevention. The objective of this prospective cohort study is to determine which factors will help the physician to confirm the diagnosis of TIA and to define the risk of stroke after a TIA.
TIA Triage Trial and Evaluation of Vascular-Specific Inflammatory BiomarkerLp-PLA2 as a Stratification Tool for TIA Triage and Stroke Risk
- - Men and Women age greater than 18 year old - Symptoms suggestive of an acute TIA
- - Patients with contraindication to brain imaging: MRI and CT. - Patient with persistent major deficit (NIHSS> or = 4) - Informed consent could not be obtained either directly from the patient or from legally authorized representative. - Severe coexisting or terminal systemic disease with like expectancy below 90 days or that may interfere with the conduct of the study.
Contact us to find out if this trial is right for you.
Stephanie Kemp, BS
View on ClinicalTrials.gov